



### Dr. Zebulon Graham, PharmD

- 1 Full-time Law Enforcement Officer; DRE-Instructor
- 2 LT-Investigation Division
- 3 Doctor of Pharmacy
- 4 BS-Biochemistry  
BS-Physics



1

---

---


---

---



---

---

---



The speaker has no disclosures.



2

---

---

---

---

---


---

---



## Alcohol Tolerance

Dr. Zeb Graham, PharmD



4

---

---

---

---

---

---

---

## Learning Objectives

- 1 Explain alcohol metabolism and describe its role in tolerance
- 2 Describe the biochemical effects of alcohol on the human brain at the molecular level
- 3 Distinguish between various types of alcohol tolerance and their mechanisms
- 4 Explain the Mellanby Effect and its implications

5

---

---

---

---

---

---

---

---

## Metabolism of Alcohol

### Key Enzymes

Alcohol Dehydrogenase  
Acetaldehyde Dehydrogenase

### Pharmacokinetics

Response of Human Body to the Presence of ETOH

7

---

---

---

---

---

---

---

---

## What Happens to Alcohol in the Human Body?

### General Metabolic Pathway

```

graph LR
    A[Ethanol (EtOH)] --> B[Acetaldehyde]
    B --> C[Acetate]
    
```

8

---

---

---

---


---

---

---

---

## The Bigger Picture-EtOH Metabolism



9

## EtOH Metabolic Products

### 1. Acetaldehyde


-Toxic byproduct of EtOH metabolism that must undergo additional metabolism

### 2. Acetate

-Can be a toxic metabolite of EtOH metabolism that ultimately is cycled into other biochemical pathways

### (1) and (2) Increase as EtOH Consumption Increases

-Various physiological consequences, both short and long term



DRUG

10

## Pharmacokinetics of EtOH

### Absorption


-Primarily through small intestine (>80%)

### Distribution

-Very small molecule (Ethanol)  
-Easily moves around the body through membranes and tissues  
-Seeks water

### Elimination


-90% is metabolized; 5-10% eliminated (unchanged) in expired air or urine



DRUG

11

### Biochemical Basis for EtOH Tolerance



- Primary (Molecular) Targets of EtOH
- EtOH Effects on the Human Brain
- EtOH Effects on Neurotransmitter Systems

DRUG INFORMATION

13

---

---

---

---

---

---

---

---

### Molecular Targets of EtOH

<b>NMDA</b> N-Methyl D-Aspartate	<b>GABA<sub>A</sub></b> Gamma-Amino Butyric Acid (subtype A)	<b>nAChRs</b> Nicotinic Acetylcholine Receptors	<b>L-Type Ca<sup>2+</sup> Channels</b>
-------------------------------------	---	--	--

DRUG INFORMATION

14

---

---

---

---


---

---

---

---

### N-MDA-R (Ionotropic)



**Glutamatergic System**  
N-MDA Receptors are an integral part of neurotransmission in the brain

**Ethanol Effects**  
DECREASES excitatory neurotransmission. Accomplished primarily by blocking Ca<sup>2+</sup> from entering intracellular space

DRUG INFORMATION

15

---

---

---

---


---

---

---

---

### GABA<sub>A</sub> (Ionotropic)



**GABAergic System**  
Gamma Amino-Butyric Acid (GABA) plays an important role in neurotransmission in the brain

**Ethanol Effects**  
INCREASES inhibitory mechanisms of neurotransmission. Accomplished primarily opening the chloride (Cl<sup>-</sup>) channel in presynaptic neurons

DRUG

16

---

---

---

---


---

---

---

---

### GABA<sub>A</sub> (Ionotropic)



DRUG

17

---

---

---

---

---

---

---


---

### EtOH and Neurotransmitters in the Brain

**Glutamate**  
Stimulates PFC, N. Ac., Amygdala, Hippocampus, Motor System

**GABA**  
Motor System, N. Ac., Amygdala

**Dopamine**  
VTA, N. Ac., PFC



DRUG

18

---

---

---

---


---

---

---

---

## EtOH Effects on Neurotransmitter Systems



19

## Classifying EtOH Tolerance

- PHARMACODYNAMIC** Overall effect(s) of EtOH on the human body
- METABOLIC** ADME of EtOH; Metabolic pathways of EtOH
- BEHAVIORAL** Management of inhibition in the presence of EtOH


DRUG

21

## Metabolic Tolerance-EtOH

### MEOS

- Microsomal Ethanol Oxidation System (MEOS)
- CYP2E1
- Liver
- ROS



DRUG

22


## Pharmacodynamic Tolerance

**CNS Alteration**

- Significant changes in neurochemical receptors, both in number and in sensitivity
- More ETOH (than before) to achieve same effects (euphoria, altered mood, etc.)

**DSM-5™**

- A need for markedly increased amounts of alcohol to achieve intoxication or desired effect
- A markedly diminished effect with continued use of the same amount of alcohol.



**DRUG**

23

---

---

---

---

---

---

---

---

## Behavioral Tolerance

Assessed by Brain and Body Interaction

**ACUTE**

15-30 minutes

**RAPID**

8-24 hours

**CHRONIC**

>24 hours of intermittent or continuous dosing

Amount of time to observe onset of tolerance after ETOH exposure

**DRUG**

24

---

---

---

---

---

---

---

---

## Tolerance-Physiology or Behavioral Response(s)?

**“**

*“The mind exercises a considerable effect upon drunkenness, and may often control it powerfully. When in the company of a superior whom we respect, or of a female in whose presence it would be indelicate to get intoxicated, a much greater portion of liquor may be withstood than in societies (i.e., company) where no such restraints operate”*

**The Anatomy of Drunkenness (1832)**  
-R. MacNish

**DRUG**

25

---

---

---

---


---

---

---


---

## Allostasis



### Maintaining Stability of the Reward Function through Constant Changes in the Reward Circuitry in the Presence of Stress (Koob; Moal)

- Homeostasis—refers to the body adjusting to the presence of a drug (EtOH) in an effort to return to baseline (normal reward function)
- When the human body is repeatedly subjected to EtOH, higher doses are required to produce the same effects (Pharmacodynamic Tolerance)
- Continual departure from homeostasis (repeated dosing of EtOH), ultimately shifts homeostatic set points and results in new setpoints being established (allostatic set points)



---

---

---

---

---

---

---

---

26

## Tolerance ≠ Dependence





---

---

---

---

---


---

---

---

27

## Mellanby Effect




**Dr. (later Sir) Edward Mellanby**

*Alcohol: Absorption into and Disappearance from the Blood under Different Conditions*

1919

### Dogs and EtOH

- 4 different dogs (of various size and similar weight) were dosed with EtOH
- Blood samples drawn from the dogs over 2 hours
- Blood-Alcohol levels determined for each dog
- Observations about dogs' impairment made for the ascending and descending limbs of the blood-alcohol curve



---

---

---

---

---


---

---

---

29





30

---

---

---

---

---

---

---

---

### Mellanby Effect

Observations	Conclusions
<ul style="list-style-type: none"> <li>Watched for dogs dragging their toenails on the ground, struggling to get up after falling down, stumbling</li> <li>Signs of intoxication were gone after 2 hours</li> <li>Signs of intoxication were observable ONLY on the ascending limb</li> <li>Noted the inherent subjectivity of assigning impairment to dogs' movement (or lack of movement)</li> </ul>	<ul style="list-style-type: none"> <li>Psychomotor impairment is more pronounced and evident on the ascending limb of the BAC curve than it is on the descending limb (at the same BAC)</li> <li>The body's CNS was the victim of 'sudden attack' (EtOH)</li> <li>CNS may have to 're-learn to coordinate its activities' after being subjected to EtOH</li> </ul>

DRUG

31

---

---

---

---

---

---

---

---

### Mellanby Effect → "ACUTE TOLERANCE"

#### Impairment only while BAC rising?

Impairment is observed on the ascending limb of the BAC because humans develop an "acute" (behavioral) tolerance to EtOH; observed impairment isn't present on descending limb of the BAC curve at the same BAC.

**Any scientific studies that support this hypothesis?**

#### A Systematic Review of the Evidence for Acute Tolerance to Alcohol—the "Mellanby Effect"

(Holland, Ferner) (2017)

- Subjects felt more intoxicated while their BAC's were rising
- Subjects didn't feel as intoxicated at the same BAC while their BAC's were declining

#### The "Mellanby Effect" in Alcoholised e-Scooter Drivers

(Zube et al.) (2022)

- 16 subjects demonstrated a "slight" Mellanby Effect when they drove a predefined course on scooters

DRUG

32

---

---

---

---

---

---

---

---

### A Systematic Review of the Evidence for Acute Tolerance to Alcohol—the “Mellanby Effect” (Holland; Ferner)

**CONCLUSIONS**

**“Mellanby Effect” Observed**

- Subjects felt a higher degree of intoxication on the ascending limb of the BAC-time curve
- Subjects were more willing to drive on the descending limb than at the same BAC observed on the ascending limb


**All EtOH Effects are Dependent**

- Drinking history
- Degree of intoxication

**DRIVING**

When measured objectively, the skills required to safely drive were “generally worse” on the descending limb of the BAC-time curve.

More willing to drive  
+  
Driving ability negatively impacted



33

---

---

---

---

---

---

---

---


### The “Mellanby Effect” in Alcoholised e-Scooter Drivers (Zube et al.)

**CONCLUSIONS**

“Slight” Mellanby Effect in E-Scooter Operators

Data Indicate a “possible” Mellanby Effect when operating an E-scooter

- 16 subjects dosed with EtOH; Blood Drawn
- Numerical score assigned to subjects as they drove a closed course



34

---

---

---

---

---


---


---

---

### EtOH Tolerance-SUMMARY

- GABAergic and Glutamatergic Systems**
  - Imbalance and Dysregulation of these Systems Offers Some Explanation of Tolerance
- Multiple Types of Tolerance**
  - Pharmacodynamic, Metabolic, Behavioral
- Tolerance vs. Dependence**
  - Not interchangeable Terms
- Mellanby Effect**
  - Feeling Less Intoxicated on the Way Down than on the Way up (BAC-time)
  - Implications for Driving Impaired





36

---

---

---

---

---

---

---

---

CONTACT ME

Zeb Graham, PHARM.D

zgraham@idahoftt.com





37

---

---

---

---

---

---

---

REFERENCES

Abouir K, Samer CF, Gloor Y, Desmeules JA and Dadi Y (2021) Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends. *Front. Pharmacol.* 12:705299. doi: 10.3389/fphar.2021.705299

American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.).


Cederbaum AI. Alcohol metabolism. *Clin Liver Dis.* 2012 Nov;16(4):667–85. doi: 10.1016/j.cld.2012.08.002. PMID: 23101976; PMCID: PMC3484320.


Dharavath RN, Pina-Leblanc C, Tang VM, Sloan ME, Nikolova VS, Pangarov P, Ruocco AC, Shield K, Voineskos D, Blumberger DM, Boleau I, Bazinoff N, Gerretsen P, Vieira E, Melamed OC, Stalile E, Quilly LC and Prevot TD (2023) GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential. *Front. Neural Circuits* 17:1216737. doi: 10.3389/fnirc.2023.1216737

Holland MG, Ferrier BE. A systematic review of the evidence for acute tolerance to alcohol – the ‘Mellanby effect’. *Clin Toxicol (Phila)*. 2017 Jul;55(5):545–556. doi: 10.1080/15563659.2017.1258574. Epub 2017 Mar 8. PMID: 28277803

Hyun J, Han J, Lee C, Yoon M, Jung Y. Pathophysiological Aspects of Alcohol Metabolism in the Liver. *Int. J. Mol. Sci.* 2021; 22: 5777. <https://doi.org/10.3390/ijms22155777>

Kalant H. Research on tolerance: what can we learn from history? *Alcohol Clin Exp Res.* 1998 Feb;22(1):67–76. doi: 10.1111/j.1530-0277.1998.tb03618.x. PMID: 9514287.





38

---

---

---

---

---

---

---

REFERENCES


Mellanby E. (1919). *Alcohol: its Absorption into and Disappearance from Blood Under Different Conditions*. London, HMSO: British Medical Research Committee. Special Report Series No. 31.


Pietrzykowski AZ, Treastman SN. The molecular basis of tolerance. *Alcohol Res Health.* 2008;31(4):298–309. PMID: 23584007; PMCID: PMC3860468.

Tabakoff B, Cornell N, Hoffman PL. Alcohol tolerance. *Ann Emerg Med.* 1989 Sep;15(5):1005–12. doi: 10.1016/s0196-0644(86)80189-6. PMID: 3526989.

Vengeliene V, Bilbao A, Molander A, Spanagel R. Neuropharmacology of alcohol addiction. *Br J Pharmacol.* 2008 May;154(2):299–315. doi: 10.1038/sjp.2008.33. Epub 2008 Mar 3. PMID: 18311194; PMCID: PMC2542440.

Zakari, P., Lybati'ric, N., Bilogajic, V., Delanc, L., Jorgic, A., Caklo, M., Bilogajic, A.B. Pharmacokinetic Analysis of Ethanol in a Human Study: New Modification of Mathematic Model. *Toxics* 2023, 11, 793. <https://doi.org/10.3390/toxics1090793>





39

---

---

---

---

---

---

---